Smoking and risk of COVID-19 hospitalization.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
06 2021
Historique:
received: 01 02 2021
revised: 07 04 2021
accepted: 11 04 2021
pubmed: 30 4 2021
medline: 27 5 2021
entrez: 29 4 2021
Statut: ppublish

Résumé

The association between smoking status and severe Coronavirus Disease 2019 (COVID-19) remains controversial. To assess the risk of hospitalization (as a marker of severe COVID-19) in patients by smoking status: former, current and never smokers, who tested positive for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV2) at an academic medical center in the United States. We conducted a retrospective cohort study in patients with SARS-COV2 between March-1-2020 and January-31-2021 to identify the risk of hospitalization due to COVID-19 by smoking status. We identified 10216 SARS-COV2-positive patients with complete documentation of smoking habits. Within 14 days of a SARS-COV2 positive test, 1150 (11.2%) patients were admitted and 188 (1.8%) died. Significantly more former smokers were hospitalized from COVID-19 than current or never smokers (21.2% former smokers; 7.3% current smokers; 10.4% never smokers, p<0.0001). In univariable analysis, former smokers had higher odds of hospitalization from COVID-19 than never smokers (OR 2.31; 95% CI 1.94-2.74). This association remained significant when analysis was adjusted for age, race and gender (OR 1.28; 95% CI 1.06-1.55), but became non-significant when analysis included Body Mass Index, previous hospitalization and number of comorbidities (OR 1.05; 95% CI 0.86-1.29). In contrast, current smokers were less likely than never smokers to be hospitalized due to COVID-19. Significantly more former smokers were hospitalized and died from COVID-19 than current or never smokers. This effect is mediated via age and comorbidities in former smokers.

Identifiants

pubmed: 33915414
pii: S0954-6111(21)00120-7
doi: 10.1016/j.rmed.2021.106414
pmc: PMC8052507
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

106414

Subventions

Organisme : AHRQ HHS
ID : R01 HS020642
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

J Virol. 2005 Feb;79(3):1966-9
pubmed: 15650225
Oncotarget. 2017 Jan 3;8(1):268-284
pubmed: 27902485
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Chest. 1999 Aug;116(2):375-9
pubmed: 10453865
Arch Intern Med. 2004 Nov 8;164(20):2206-16
pubmed: 15534156
Ann Am Thorac Soc. 2021 Aug;18(8):1326-1334
pubmed: 33724166
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32366490
Chest. 2013 Jan;143(1):196-206
pubmed: 23276842
Inflammation. 2011 Aug;34(4):231-7
pubmed: 20625922
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Am J Public Health. 1993 Sep;83(9):1277-83
pubmed: 8363004
BMJ Evid Based Med. 2021 Dec;26(6):279-284
pubmed: 32788164
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 1982 Oct 21;307(17):1042-6
pubmed: 7121513
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
Am J Public Health. 1994 Nov;84(11):1750-6
pubmed: 7977912
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Lancet. 2003 Aug 16;362(9383):507-15
pubmed: 12932381
Intern Emerg Med. 2020 Aug;15(5):853-856
pubmed: 32430652
Tuber Lung Dis. 1996 Dec;77(6):570
pubmed: 9039455
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-1559
pubmed: 32329629
Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R895-R906
pubmed: 30088946
Thorax. 2021 Jul;76(7):714-722
pubmed: 33402392
N Engl J Med. 2000 Mar 9;342(10):681-9
pubmed: 10706897
J Adolesc Health. 2020 Sep;67(3):362-368
pubmed: 32674964
Lancet. 2013 Jan 12;381(9861):133-41
pubmed: 23107252
Am J Public Health. 1981 May;71(5):530-2
pubmed: 7212144
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Int J Obes (Lond). 2020 Sep;44(9):1807-1809
pubmed: 32647359
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Am J Respir Crit Care Med. 2020 Aug 1;202(3):471-472
pubmed: 32530714
Am J Health Promot. 2000 Jul-Aug;14(6):357-61
pubmed: 11067570
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821
pubmed: 32584597
Chest. 2018 Feb;153(2):575-578
pubmed: 29406227
Tubercle. 1988 Jun;69(2):105-12
pubmed: 3188230
Eur J Intern Med. 2020 May;75:107-108
pubmed: 32192856
Am J Epidemiol. 1969 Nov;90(5):390-9
pubmed: 5356947

Auteurs

Daniel Puebla Neira (D)

Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Texas Medical Branch. Galveston, TX, USA. Electronic address: dapuebla@utmb.edu.

Abigail Watts (A)

Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Texas Medical Branch. Galveston, TX, USA.

Justin Seashore (J)

Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Texas Medical Branch. Galveston, TX, USA.

Efstathia Polychronopoulou (E)

Office of Biostatistics, University of Texas Medical Branch. Galveston, TX, USA.

Yong-Fang Kuo (YF)

Office of Biostatistics, University of Texas Medical Branch. Galveston, TX, USA; Sealy Center on Aging, University of Texas Medical Branch. Galveston, TX, USA.

Gulshan Sharma (G)

Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Texas Medical Branch. Galveston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH